33
Stefania Abbruzzetti Dipartimento di Scienze Matematiche, Fisiche e Informatiche Università di Parma, Parma, Italy e-mail: [email protected] Protein-based nanocarriers for photodynamic therapy and subdiffraction localization of the theranostic agent

Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

  • Upload
    others

  • View
    3

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Stefania Abbruzzetti

Dipartimento di Scienze Matematiche,

Fisiche e Informatiche

Università di Parma, Parma, Italy

e-mail: [email protected]

Protein-based nanocarriers for photodynamic

therapy and subdiffraction localization of the

theranostic agent

Page 2: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Cristiano Viappiani

Pietro Delcanale

Chiara Montali

Stefano Bruno

Massimiliano Tognolini

Marco Cozzolino

Paolo Bianchini

Alberto Diaspro

Santi Nonell

Beatriz Rodriguez-Amigo

Paolo Foggi

F. Javier Luque

Axel Bidon-Chanal

Page 3: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Develop of nanoscaled

chemical constructs that

have simultaneously

therapeutical and

diagnostical functions

Page 4: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

This theranostic approach is particularly interesting for PDT

Page 5: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Principi PDT

Photodynamic effect

Nature Reviews Cancer 2003, 3, 380-387

Page 6: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

photosensitizer molecular oxygen

High extinction in the red/NIR

High

No dark toxicity

High bioavailability

The ideal

photosensitizer

= T S

P. Ogilby, Chem. Soc. Rev.,

2010, 39, 3181–3209

158 kJ/mole

Page 7: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Photodynamic therapy of tumors

clinically approved, minimally invasive therapeutic procedure that

can exert a selective cytotoxic activity toward malignant cells.

3 s d 100 nm

P. Agostinis et al. CA Cancer J Clin., 2011, 61 (4), 250, 281.

Page 8: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Protein based carriers for photodynamic therapy

Page 9: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

1O2

1O2

Stable and easily obtained human protein (myoglobin)

Well known natural photosensitizer (hypericin)

Page 10: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Hyp

Fe-protoporfirin IX

Hypericin is very similar

to heme in size, shape,

symmetry and

hydrophobicity.

This suggests that the

apo-protein could form a

stable complex with Hyp.

Page 11: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

600 700 8000.0

0.5

1.0

1.5

Flu

ore

sce

nce

(a.u

.)

Wavelength (nm)

600 700 8000.0

0.5

1.0

1.5

Flu

ore

scen

ce(a

.u.)

600 700 8000.0

0.5

1.0

1.5

Flu

ore

scen

ce(a

.u.)

Hyp spontaneously binds to

apoMb in a 1:1 complex with

moderately high affinity.

Upon binding to apoMb

fluorescence emission is

recovered, similar to ethanol

F=0.14

J. Comas-Barceló et al.

RSC Advances, 2013, 3, 17874-17879.

Hyp-ApoMb complex

Page 12: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Ka=(2.4±0.5)105 M-1

Kd =(4.2±0.8) M

Hyp+ApoMb kb

k-b

Hyp-ApoMb

600 7000.0

0.5

1.0

1.5

A

Flu

ore

sce

nce

(a.u

.)

Wavelength (nm)

0 10 20 300

2

4

6

F(a

.u.)

[apoMb]( M)0 10 20 30

0

2

4

6

F(a

.u.)

[apoMb]( M)

Hyp to apoMb binding

Page 13: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Excitation fluorescence anisotropy

em = 620 nm

400 500 600-0.1

0.0

0.1

0.2

0.3

An

iso

tro

py

wavelength (nm)

400 500 600-0.1

0.0

0.1

0.2

0.3

An

iso

tro

py

wavelength (nm)

Hyp in ethanol

Hyp-apoMb in PBS

S0→ S2

S0→ S1

Page 14: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Triplet-triplet transient absorbance

Hyp-ApoMb in air saturated PBS buffer

Hyp in air saturated DMSO

1.5 s

0.1 1 10 100

0.00

0.01

A(5

20

nm

)

Time( s)

0.1 1 10 100

0.00

0.01

11.5 s

Reactive states formation

Page 15: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

APBT

Antibacterial photosensitization-based treatment

Page 16: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Excellent photoinactivation was observed with other Gram positive

bacteria like Listeria monocytogenes

Bacterial photoinactivation

B. subtilis

Hyp

Hyp-apoMb

S. aureus

B. subtilis

E. coli

Hyp = 10 M, ApoMb = 30 M

Page 17: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

300 400 500 600 700 8000.00

0.05

0.10

0.15A

bs o

r F

luo

wavelength (nm)

Excitation

566 nm

STED

715 nm

Emission

=

Excitation STED

pattern

Effective

PSF

Page 18: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

P. Delcanale, et al. Sci. Rep., 2015, 5, 15564.

STED imaging of Hyp-apoMb

521 nm

excited state absorption

647 nm

stimulated emission

592 nm

ground state bleaching

Page 19: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

confocal STED

B. subtilis

STED beam = 715 nm

Excitation = 566 nm

Detection = 605/70 nm

Improvement in resolution

2.5 m 2.5 m

Page 20: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

B. subtilis

E. coli

S. aureus

Gram-

Gram+

Gram+

Page 21: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Changing the scaffold

Page 22: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

-Lactoglobulin

(2 LG)

KD = 8.6 µM-1

B. Rodríguez-Amigo et al. J. Dairy Sci., 2015, 98, 89–94.

Proteins may be endowed with multiple binding sites

Typical case is the dimeric protein -lactoglobulin

Internal binding site (e.g. retinoic acid) and clefts at dimer

interface

Page 23: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Hyp in DMSO

Hyp in PBS

Hyp + 2 LG

Hyp binding to 2 LG

Kd = 0.71±0.03 µM.

Page 24: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Light dose effects on S. aureus photoinactivation

by the complex Hyp- 2 LG for Hyp (8 µM) and 2 LG (40 µM).

Bacterial photoinactivation

Page 25: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Absorption and fluorescence emission

suggest non perfect solvation

Multiple binding at each cleft

Solvent exposure of Hyp bound at the large cleft

Page 26: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Preferential distribution of DMSO molecules around the protein

surface of dimeric LG.

DMSO density of 0.3 g cm3.

Amino acids with hydrophobic side chains.

Tuning local solvent composition at the

protein surface

Page 27: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Delcanale, P. et al. Journal of Materials Chemistry B, 2017, 5 (8), 1633-1641.

Preferential distribution of DMSO

molecules around the protein

surface of dimeric LG bound to Hyp

molecules as monomers in the

narrow cleft, and either (A) monomer

or (B) dimer in the wide cleft.

Page 28: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

400 500 600 7000.00

0.02

0.04

0.06

600 650 7000

20

40

60

80

100

Ab

so

rba

nce

Em

issio

n (

a.u

.)

400 500 600 7000.00

0.02

0.04

0.06

600 650 7000

20

40

60

80

100

Ab

so

rba

nce

Em

issio

n (

a.u

.)

400 500 600 7000.00

0.02

0.04

0.06

600 650 7000

20

40

60

80

100

Ab

so

rba

nce

Em

issio

n (

a.u

.)

400 500 600 7000.00

0.02

0.04

0.06

600 650 7000

20

40

60

80

100

Ab

so

rba

nce

Em

issio

n (

a.u

.)

400 500 600 7000.00

0.02

0.04

0.06

600 650 7000

20

40

60

80

100

Ab

so

rba

nce

Em

issio

n (

a.u

.)

Hyp in DMSO

Hyp in PBS

Hyp in 20% PBS–DMSO

Hyp2 LG in PBS

Hyp2 LG in 20% PBS–

DMSO

Absorption and Fluorescence emission indicate better

solvation of Hyp when bound to 2 LG.

Further improvement is observed when DMSO is

added

Spectral improvements for mixed solvents?

Page 29: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

400 450 500 550 600-0.2

0.0

0.2

Anis

otr

opy

400 450 500 550 600-0.2

0.0

0.2

Anis

otr

opy

400 450 500 550 600-0.2

0.0

0.2

Anis

otr

opy

Hyp in DMSO

Hyp2bLG in PBS

Hyp2bLG in 20% PBS–

DMSO

The interaction with the protein is fundamental

for the observed spectral improvement

No anisotropy observed in the absence of the protein

Page 30: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

10-4

10-2

100

102

0.0

0.5

1.0

1.5

2.0

G

10-2

100

102

0.0

0.1

0.2

0.3

(ms)

D = 70 μm2/s

Hyp bound to

2βLG

D = 40 μm2/s

Hyp bound to 2βLG

higher viscosity of the mixture

different hydrodynamic radius of the DMSO-

coated protein.

FCS demonstrates formation of the complex

Hyp-2 LG

PBS PBS-DMSO

Page 31: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

sample solvent τF (ns) ФF τT (μs) ФT τΔ (μs) ФΔ

Hyp DMSO 5.5±0.1 (100%)

0.35±0.02 12 1.4±0.1* 0.35 13 5.5±0.1 0.28±0.05 29

Hyp PBS + S. aureus 0.2 (48%) 4.2 (52%)

Hyp PBS-DMSO 20%

3.5 (100%)

+ S. aureus 0.5 (48%) 3.6 (52%)

Hyp2βLG PBS 3.9 (35%) 6.7 (65%)

0.03±0.01 10±2* 8.6 & 9.6 £

0.050±0.002 2.3±0.1 0.065±0.010

+ S. aureus 4.6 (45%) 7.0 (55%)

8±1 *

Hyp2βLG PBS-DMSO 20%

0.2 (20%) 5.6 (80%)

0.06±0.01 8.2±0.4* 8.4 & 7.5 £

0.170±0.002 2.5±0.1 0.123±0.05

+ S. aureus 5.5 (100%) 9±1 *

*: Laser Flash Photolysis; &:Time-Resolved NIR phosphorescence detection; £:Fluorescence Correlation Spectroscopy

Photophysical parameters of Hyp and Hyp2βLG in

PBS or PBS-DMSO 20% incubated with S. aureus

cells

Page 32: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

0 10 20 3010

-8

10-6

10-4

10-2

100

CF

U/m

L

Light Dose (J/cm2)

A

0 10 20 30 40

B

Unexpectedly, bioavailability is decreased

Hyp

Hyp-2 LG

PBS PBS-DMSO 20%

S. aureus

Page 33: Protein-based nanocarriers for photodynamic therapy and ...400 500 600 700 0.00 0.02 0.04 0.06 600 650 700 0 20 40 60 80 100 ce on (a.u.) Hyp in DMSO Hyp in PBS Hyp in 20% PBS–DMSO

Funding